Webinar Description:

The progressive deposition of misfolded Tau protein is a pathological hallmark of several neurodegenerative diseases, collectively called tauopathies, with Alzheimer’s disease being the most prevalent. Despite the progress of research in this field, the underlying molecular mechanisms governing the intercellular aggregation and spreading of Tau assemblies remain elusive. Major limitation has been the translation of mechanistic findings from clonal cell lines, where high throughput screening approaches are more readily available, to functional neuronal models that replicate the phenotypes observed in disease conditions. To address this issue, the aim of our work has focused on the development of functional neuronal screening assays. Challenges and progress of this work will be presented and discussed in line of future opportunities for technical advancements.

Thursday Dec 6 @ 11 am EST – Register for the webinar


Learning Objectives:

  • Learn about Cellectricon’s new assay platform for functional modelling of prion-like mechanisms
  • Learn about assays and platforms that enable phenotypic screening to identify modifiers of Tau uptake and propagation through genetic and pharmacologic screens
  • Learn more about functional neuronal models to study Tau pathology in relevant neuronal assays using e.g. multichannel microfluidic setups


Speakers:

Thomas Jahn, PhD, Group Leader, Neuroscience Drug Discovery at AbbVie, Germany
Following a Diploma in Biochemistry from the University of Halle (Germany), Thomas moved to the University of Leeds (UK) to receive his PhD in Structural Biology of protein misfolding. Being awarded a Sir Henry Wellcome Postdoctoral Fellowship, he subsequently moved to the University of Cambridge (UK) to work in the Departments of Chemistry and Genetics. During this time, he established a cross-disciplinary team to develop innovative ways to develop and analyze novel models of protein misfolding, with a major focus on Alzheimer’s and Parkinson’s Disease. In 2011 Thomas received funding to establish his independent research group at the University of Heidelberg (Germany). Here, the main research interest of his group focused on proteostasis in neurodegenerative disease, by providing novel methods to recapitulate human disease aspects using cellular and Drosophila models. Thomas joined AbbVie in 2015 where he is a Group Leader in the Neuroscience Discovery organization in Ludwigshafen (Germany).

Sebastian Illes, PhD, Director of CNS research at Cellectricon, Sweden
Sebastian joined Cellectricon in 2018 as director of CNS research. Previously, he held a position as research project leader at the University of Gothenburg. Sebastian did his Post-Doc at the Institute for Molecular Regenerative Medicine (PMU, Salzburg, Austria) and worked as guest researcher at the Natural and Medical Science Institute, Reutlingen, Germany. He holds a diploma in biology with specialisation of neurodevelopment (Ruhr-University-Bochum, Germany) and did his PhD at the neurology department at the Heinrich-Heine University, Duesseldorf, Germany, where he combined for the first time pluripotent stem cell-derived neurons with microelectrode array technology with the specific application in pre-clinical research. Sebastian is still affiliated to University of Gothenburg where he is conducting independent research on human iPSC-derived neuronal circuit models for bipolar disorder, schizophrenia and Alzheimer‘s disease.

Launch of novel, high throughput in vitro platform will help researchers find molecules that can prevent prion-like spreading of neurodegenerative disease associated peptides.

Cellectricon AB, a collaborative research organization dedicated to advancing drug discovery and research in the areas of chronic pain and CNS diseases, today announced the launch of a novel assay platform for in vitro neurodegenerative disease research. The platform, based on a patent-pending microfluidics technology, has been developed over the past two years in collaboration with a leading pharmaceutical company.

“The propagation of neurodegenerative disease associated peptides (NDAPs), such as tau and alpha-synuclein, within the brain is considered to be one of the major pathological mechanisms in progressive neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease”, said Dr. Sebastian Illes, Director of CNS Research at Cellectricon.  “With our new platform, we can model these neuropathological processes and we have the capacity and robustness to allow screening and profiling of larger compound sets in the search for molecules preventing prion-like spreading of NDAPs in neuronal circuits. We believe this will provide many new opportunities for the development of highly differentiated therapeutics for several neurodegenerative diseases.”

Cellectricon has successfully supported pharmaceutical companies and academic institutions for over five years with assay development, screening and preclinical compound validation for their pain and CNS disease projects. With the launch of its new assay platform, Cellectricon has significantly expanded the research opportunities available to customers working on progressive neurodegenerative diseases.

“We are extremely pleased to add this assay platform to our portfolio as it enables us to extend our services offering to encompass neurodegenerative disease research”, said Dr Mattias Karlsson, Cellectricon’s CEO. “With our new and patent-pending assay platform, we can create highly relevant, complex disease models and innovative assays for functional and morphological screening, and we are looking forward to discussing the new research possibilities that it opens up with delegates at Neuroscience in San Diego.”

To find out more, visit the Cellectricon booth #1331 at Neuroscience 2018, San Diego, CA, USA (3-7 November). Cellectricon is also presenting several posters at Neuroscience, and full details of our poster presentations can be found at www.cellectricon.com/neuroscience-2018/

For more information on Cellectricon’s Pain and CNS Discovery Services, please visit www.cellectricon.com

AD/PD 2019, the 14th​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders takes place in Lisbon, Portugal on March 26-31, 2019.

Additional information on meeting opportunities and poster presentations from Cellectricon will be added closer to the event.

Visit event site

The conference focused on discussing the latest technologies in the preclinical, translational neuroscience space and also new innovations happening in translational neuroscience imaging.

Paul Karila, CSO & Director, chronic pain research, gave a presentation on Oct 4, 2018 titled:

Novel approaches and concepts for development of functional in vitro assays targeting neurodegenerative disease discovery

The talk covered:

  • Combining primary and stem cell-derived neuronal cell cultures with optical electrophysiology to produce complex assays for functional screening
  • Microsystems engineering approaches for generation of compartmentalized cell cultures for high capacity screening
  • Multiparametric data analysis of combined optical electrophysiology and high content imaging data to cover both functional and morphological aspects of disease

Visit event site